|
Name |
(5alpha,6beta,15beta,22E)-6-ethoxy-5,15-dihydroxyergosta-7,22-dien-3-one
|
Molecular Formula | C30H48O4 | |
IUPAC Name* |
(5R,6R,9S,10R,13R,14R,15R,17R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-6-ethoxy-5,15-dihydroxy-10,13-dimethyl-2,4,6,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-one
|
|
SMILES |
CCO[C@@H]1C=C2[C@H](CC[C@]3([C@H]2[C@@H](C[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)O)C)[C@@]4([C@@]1(CC(=O)CC4)O)C
|
|
InChI |
InChI=1S/C30H48O4/c1-8-34-26-15-22-23(29(7)14-11-21(31)17-30(26,29)33)12-13-28(6)24(16-25(32)27(22)28)20(5)10-9-19(4)18(2)3/h9-10,15,18-20,23-27,32-33H,8,11-14,16-17H2,1-7H3/b10-9+/t19-,20+,23-,24+,25+,26+,27+,28+,29+,30-/m0/s1
|
|
InChIKey |
FPESVMYWFTWXKH-BLMRKQJBSA-N
|
|
Synonyms |
(5alpha,6beta,15beta,22e)-6-ethoxy -5,15-dihydroxyergosta-7,22-dien-3-one; (5alpha,6beta,15beta,22E)-6-ethoxy-5,15-dihydroxyergosta-7,22-dien-3-one
|
|
CAS | NA | |
PubChem CID | 137797617 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 472.7 | ALogp: | 4.7 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 66.8 | Aromatic Rings: | 4 |
Heavy Atoms: | 34 | QED Weighted: | 0.476 |
Caco-2 Permeability: | -4.799 | MDCK Permeability: | 0.00004360 |
Pgp-inhibitor: | 0.738 | Pgp-substrate: | 0.854 |
Human Intestinal Absorption (HIA): | 0.116 | 20% Bioavailability (F20%): | 0.905 |
30% Bioavailability (F30%): | 0.779 |
Blood-Brain-Barrier Penetration (BBB): | 0.034 | Plasma Protein Binding (PPB): | 82.14% |
Volume Distribution (VD): | 1.132 | Fu: | 1.92% |
CYP1A2-inhibitor: | 0.031 | CYP1A2-substrate: | 0.494 |
CYP2C19-inhibitor: | 0.04 | CYP2C19-substrate: | 0.822 |
CYP2C9-inhibitor: | 0.276 | CYP2C9-substrate: | 0.063 |
CYP2D6-inhibitor: | 0.004 | CYP2D6-substrate: | 0.099 |
CYP3A4-inhibitor: | 0.848 | CYP3A4-substrate: | 0.732 |
Clearance (CL): | 1.859 | Half-life (T1/2): | 0.335 |
hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.445 |
Drug-inuced Liver Injury (DILI): | 0.609 | AMES Toxicity: | 0.012 |
Rat Oral Acute Toxicity: | 0.814 | Maximum Recommended Daily Dose: | 0.561 |
Skin Sensitization: | 0.03 | Carcinogencity: | 0.002 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.022 |
Respiratory Toxicity: | 0.88 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004757 | 0.530 | D0G5CF | 0.381 | ||||
ENC005438 | 0.530 | D0G8OC | 0.376 | ||||
ENC001984 | 0.530 | D06JPB | 0.354 | ||||
ENC004804 | 0.530 | D0N1TP | 0.299 | ||||
ENC003121 | 0.483 | D0Y7LD | 0.296 | ||||
ENC006034 | 0.483 | D08SVH | 0.279 | ||||
ENC005016 | 0.479 | D01QUS | 0.268 | ||||
ENC004735 | 0.458 | D0X7XG | 0.265 | ||||
ENC001092 | 0.445 | D0Q6NZ | 0.254 | ||||
ENC004738 | 0.445 | D0KR5B | 0.254 |